Grufity logo
Grufity logo
LPTX

LPTX - Leap Therapeutics Inc Stock Price, Fair Value and News

$2.58+0.31 (+13.66%)
Delayed as of 14 Sep 2026, 04:00 pm ET

20/100

LPTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

20/100

LPTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LPTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LPTX Price Action

Last 7 days

-6.2%

Last 30 days

243.9%

Last 90 days

249.2%

Trailing 12 Months

710.7%

LPTX RSI Chart

LPTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LPTX Valuation

Market Cap

278.0M

Price/Earnings (Trailing)

-317.03

Price/Sales (Trailing)

101.93

EV/EBITDA

215.12

Price/Free Cashflow

-13.2

LPTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LPTX Fundamentals

LPTX Revenue

Revenue (TTM)

2.6M

LPTX Earnings

Earnings (TTM)

-877.0K

Earnings Growth (Yr)

336.67%

Earnings Growth (Qtr)

151.04%

LPTX Profitability

EBT Margin

48.19%

Return on Equity

-0.63%

Return on Assets

-0.61%

Free Cashflow Yield

-7.57%

LPTX Investor Care

Shares Dilution (1Y)

160.05%

Diluted EPS (TTM)

0.56

Revenue & Growth

How Leap Therapeutics Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
2025----
20243.4M2.5M2.3M2.6M
20231.8M2.9M3.6M4.0M
20221.4M1.2M1.1M925.0K
20211.5M1.5M1.5M1.5M
2020464.0K796.0K1.1M1.5M
2019600.0K444.0K288.0K132.0K
20181.5M1.2M995.8K756.0K
20172.8M2.4M2.1M1.7M
2016---3.1M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Leap Therapeutics Inc

LPTX
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
 CEO
 WEBSITEleaptx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES44

Leap Therapeutics Inc Frequently Asked Questions

LPTX is the stock ticker symbol of Leap Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of Leap Therapeutics Inc is 278.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, LPTX's PE ratio (Price to Earnings) is -317.03 and Price to Sales (PS) ratio is 101.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LPTX PE ratio will change depending on the future growth rate expectations of investors.